Company profile
Aequus Pharmaceuticals Inc.
OTC: AQSZF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#944 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ —GM —SS 34
v0.1 · 5/100 weight · pillars only
↑ revenue growth (YoY), disclosure history · ↓ Altman-Z, balance-sheet leverage
Methodology →Revenue TTM
$657.0k
Rev growth YoY (TTM)
+116.8%
Net income (FY)
-$1.6M
Employees
12
as of 2026-08-27
Market cap
$92.8k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$426.5k584.2k CAD2024
Net income-$1.6M-2.2M CAD2024
Operating income-$1.6M-2.1M CAD2024
Total assets$556.2k800.3k CAD2024
Liabilities$5.0M7.3M CAD2024
Equity-$4.5M-6.5M CAD2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aequus Pharmaceuticals Inc.’s revenue?
Aequus Pharmaceuticals Inc. booked $426.5k in FY2024 revenue, growing 126% year over year — faster than most Healthcare companies we track, at a -372.7% net margin.
Peers · Healthcare
Alternate Health Corp.——Scienture Holdings, Inc.50DNiki BioSolutions, Inc.32DAmarantus BioScience Holdings, Inc.——MediciNova, Inc.41DCartesian Therapeutics, Inc.40DKey facts
CEODouglas Glen Janzen
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: AQSZF
Employees12
IPO date2015-06-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.